Kornimate/medical-research-clean huggingface dataset:
ferumoxytol as a contrast agent for pulmonary magnetic resonance angiography

Conditions: Pulmonary Embolism

Summary: this proposal is based on findings from our previous work involving ferumoxytol-enhanced cardiac magnetic resonance angiography. the resolution of the pulmonary vasculature based on our previous imaging protocol was exceptional (pmid: 26786296). in the partners healthcare system between january 1, 2014 and january 1, 2015 there were 541 patients evaluated in partners healthcare-affiliated hospitals with a diagnosis of pulmonary embolism and acute or chronic kidney disease at the same visit between 01/01/2014 and 01/01/2015. ventilation perfusion scanning was performed in 201 patients during this same time interval. up to 63% of these patients in one year did not receive the diagnostic test of choice.

thromboembolic events in patients with chronic kidney disease are out of proportion to age matched controls occurring 2.34 times more frequently than in non-ckd patients (pmid 19561505). at the same time, patients with kidney disease are not offered the gold standard for pulmonary embolus diagnosis, i.e. ct angiography, for concern of acute dialysis to treat contrast-induced nephropathy. ventilation perfusion scintigraphy (v/q) is the preferred diagnostic test for patients with advanced ckd (glomerular filtration rate \<30ml/min/m2) and suspicion of pulmonary embolus, but can not be utilized if pulmonary parenchyma contains interstitial edema or alveolar occlusion due to pneumonia. if diagnostic tools for pulmonary embolus are not available, patients are subject to the risk of empiric treatment to avoid life-threatening complications of untreated pulmonary embolus. for those patients with ckd that undergo ct angiography, they are placed at risk of initiating dialysis. if this occurs multiple financial costs are associated with dialysis catheter placement and acute hemodialysis. if a patient instead is evaluated with gadolinium-based contrast modalities, there is the risk of nephrogenic systemic fibrosis and the morbidity associated with this iatrogenic disease process. ferumoxytol-enhanced mri could avoid the risk of iodinated contrast and gadolinium contrast and accelerate the diagnosis and treatment of patients with pulmonary embolus.

Eligibility criteria:
inclusion criteria: * patients with a clinical suspicion for pulmonary embolus * estimated glomerular filtration rate (egfr) \<30ml/min/1.73m2 * have been clinically disqualified from the use of iodine-based contrast studies, gadolinium-based contrast studies or nuclear-based detection studies exclusion criteria: * received ferumoxytol in the previous six months * anaphylactic reaction to other intravenous iron formulations * calculated estimated glomerular filtration rate is \>50ml/min/1.78m2 * patients on dialysis with no residual renal function * pregnant women and nursing mothers. standard screening will be used by * patients \>65 years of age with bmi \>45, and/or liver disease (child-pugh class c)
erigo® life- control of cardiovascular parameters via verticalization and simultaneous mobilization

Conditions: Stroke; Spinal Cord Injury

Summary: early verticalization and stepping with the equipment of hocoma erigo during monitoring of vital parameters. the device is already ce marked and, for the purposes of the study, will be used in accordance with the intended use (after-market clinical investigation).

in early rehabilitation of neurological patients, safe mobilization and intensive sensorimotor stimulation are key factors for therapeutic success. early activation and stimulation of the patient intend enhancement of neuroplasticity and recovery. furthermore, it improves the patient's communication and cooperation skills and counteracts secondary damages due to immobilization. the study combines gradual verticalization during monitoring of vital parameters, with cyclic leg movement and foot loading. the table to ensures the necessary safety for the stabilization of the patient in the upright position. the patient stimulation is additionally enhanced by synchronized functional electrical stimulation (fes). by providing a safe solution for early mobilization, the erigo counteracts the negative effects of immobility and accelerates the recovery process through intensive sensorimotor stimulation. it is the first choice therapy device for the early and safe mobilization of severely impaired, bed-ridden patients even in acute care.

Eligibility criteria:
inclusion criteria: * minimum 18 years old * normal response to verbal instructions * oxygen saturation of the blood at least 92% * healthy german speaking men and women * non-smoker * heartbeat 40-100 * systolic blood pressure 120 to 220 mmhg * in patients: post acute phase: stroke or other neurological functional disorder exclusion criteria: * severe contraction in the legs (ashworth \>3) * pregnancy * acute pain syndrome * severe cardio-pulmonary disease * history of orthostatic dysregulation * thrombophlebitis * diabetes * renal disease * contraindication for electric stimulation (instable epilepsy, cancer, pacemaker, palliative care) * weight \> 120kg * height \> 210 cm * skin lesions on legs

Keywords: brain injury, early rehabilitation, tilt table
acceptable pressure range for continuous positive airway pressure(cpap) treatment

Conditions: Obstructive Sleep Apnea of Adult

Summary: compliance of continuous positive airway pressure （cpap） derived from auto-titration is similar to that derived from manual titration, although pressure derived from the former was usually 2-5 cmh2o higher than the latter. therefore the investigators hypothesize that accurate titration maybe not necessary for successful treatment of obstructive sleep apnea (osa) as long as cpap pressure was not lower than the minimal effective pressure.

study design: a randomized, cross-over and double-blind study. objective: to compare the pressure of 10 cmh2o and minimal effective pressure derived from manual titration on the effect of cpap treatment in osa. methods: patients with suspected osa (age, body mass index and symptom) to be referred to a sleep centre were recruited. patients with osa confirmed by overnight full polysomnography (psg) were invited to do standard overnight manual titration under psg based on the academy of sleep medicine (aasm) manual guidelines. patients whose manual titration pressure lower than 10cmh2o and willing to participate in the study were invited to repeat two more nights (3th psg and 4th psg) under cpap pressure at both 10cmh2o and the pressure derived from manual titration in random order. the sleep apnea-hypopnea index (ahi), obstructive sleep apnea index (ohi), arousal index (ari), oxygen desaturation index (odi), sleep structure, and treatment preference were to be observed.

Eligibility criteria:
inclusion criteria: 1. reported snore, apnea and daytime sleepiness; 2. a diagnosis of obstructive sleep apnea with polysomnography according to assm guideline(apnoea-hypopnea-index(ahi)≥5 events/h) and need to be treated with continuous positive airway pressure; 3. willing to participate after informed consent. exclusion criteria: 1. evidence of severe coronary or cerebral, cardiovascular disease and significant memory, perceptual or behavioural disorder; 2. severe respiratory disease defined as severe chronic obstructive pulmonary disease(ie. fev1/fvc\<70% and fev1\<50%predicted) or resting awake sao2\<90% 3. have known contraindications with cpap, like current pneumothorax and hemoptysis, et al. 4. central sleep apnea\>10 events/h； 5. frequent nasal congestion； 6. optimal treatment cpap pressure(by manual titration) equal or higher than 10cmh2o.

Keywords: osa cpap acceptable range
central venous catheter-related complications in patients under anticancer treatment

Conditions: Central Venous Catheter Thrombosis; Central Venous Catheter Related Bloodstream Infection; Solid Tumor; Hematologic Malignancy

Summary: oncology and hemotology patients under anticancer treatments are exposed to increased risks of central venous catheter-related complications due to the underlying cancer and its treament. this prospective observational monocentric french study aims at describing the incidence of such complications, their morbimortality, and analyzing some risk factors in order to contribute to propose some strategies to reduce these complications' rate and consequences


Eligibility criteria:
inclusion criteria: all patients older than 18 years, with solid cancer or hematological malignancy receiving anticancer treatment in the outpatient medical department of alpes leman hospital and having a central venous catheter been placed between the 11th of july 2022, and the 1st of january 2023.
cerebral embolic load in patients undergoing surgical aortic valve replacement: a comparison of the conventional with the minimized extracorporeal circulation technique using transcranial doppler ultrasound

Conditions: Aortic Valve Stenosis; Extracorporeal Circulation

Summary: in this study, the investigators aim to compare cerebral embolic load in patients undergoing surgical aortic valve replacement using either the minimized extracorporeal circulation or the conventional extracorporeal circulation technique. the detection of cerebral emboli is performed not-invasively by transcranial doppler detection of high-intensity transient signals representing solid or gaseous microembolism in the middle cerebral arteries. the investigators hope to get more insight in the mechanism (incl. quantity) of cerebral embolism during aortic valve surgery using extracorporeal circulation.

background the gold standard to treat severe aortic valve stenosis is currently the surgical aortic valve replacement (savr) using conventional extracorporeal circulation (cecc). savr, however, can be performed also on minimized extracorporeal circulation (mecc), which is characterized by reduced priming volume and interfaces between blood and artificial surfaces and blood-air interface, respectively. further technical developments of the mecc system together with reports on less induction of the coagulation cascade and activation of inflammatory systemic response may account for a reduced incidence of microbubble generation with mecc system. objective the aim of the is to investigate the procedural-related incidence of high-intensity transient signals (hits) representing solid or gaseous microembolism reaching the cerebral vessels. methods patients undergoing savr are included in the study and randomised to either mecc or cecc technique. hits are continuously bilaterally detected during the entire intraoperative period by transcranial doppler ultrasound.

Eligibility criteria:
inclusion criteria: * isolated severe aortic valve stenosis * no other cardiac disease * no other coronary heart disease * written informed consent exclusion criteria * double valve surgery * concomitant coronary artery bypass surgery * vascular surgery * age \< 18 yrs. * age \> 80 yrs.

Keywords: intracranial embolism ultrasonography, doppler, transcranial
18f sodium fluoride pet/ct in acute aortic syndrome

Conditions: Acute Aortic Syndrome; Aortic Dissection; Penetrating Aortic Ulcer; Intramural Hematoma

Summary: the purpose of this study is to determine whether sodium fluoride imaging (using positron emission tomography-computed tomography - pet-ct) is able to predict disease progression in acute aortic syndrome.

acute aortic syndrome encompasses multiple aortopathies, including aortic dissection, intramural haematoma and penetrating aortic ulcers. acute aortic syndrome has a three year mortality approaching 25%. to date, other than the initial aortic diameter, there are no accurate methods of establishing the risk of disease progression in patients with acute aortic syndrome. in vascular disease, microcalcification occurs in response to necrotic inflammation. using computed tomography and positron emission tomography (pet-ct), early microcalcification can be identified using uptake of the radiotracer 18f-sodium fluoride. this can identify high risk-lesions in the aorta, coronary and carotid arteries, and appears to be indicative of necrotic and heavily inflamed tissue. in abdominal aortic aneurysms, 18f-sodium fluoride binding predicts aortic expansion and the risk of aneurysm rupture or requirement for surgical repair. the study investigators, therefore, propose to evaluate the ability of 18f-sodium fluoride to identify regions of necrotic inflammation in acute aortic syndrome to predict aortic expansion and disease progression. control patients with a normal calibre aorta will be recruited from the national abdominal aortic aneurysm screening programme and vascular out-patient clinics. patients with acute aortic syndrome and chronic aortic disease will undergo clinical assessments and 18f sodium fluoride pet/ct scans at baseline and 12-months. clinical follow-up will continue for up to 3 years from recruitment.

Eligibility criteria:
inclusion criteria: patients with acute aortic syndrome or chronic aortic disease: * a diagnosis of acute aortic syndrome as defined as per the european society of cardiology guidelines on the management of aortic disease a compatible clinical presentation with ct or magnetic resonance imaging confirming acute aortic syndrome. * adults over the age of 25 years * participants who have had previous open or thoracic endovascular aortic repair (tevar) are eligible to participate in the study. healthy controls: * no previous diagnosis of aortic disease * over the age of 55 years exclusion criteria: * the inability of patients to undergo pet/ct scanning * chronic kidney disease (egfr ≤ 30 ml/min/1.73 m2) * major or untreated cancer * pregnancy * allergy or contra-indication to iodinated contrast * inability or unwillingness to give informed consent

Keywords: sodium fluoride positron emission tomography computed tomography acute aortic syndrome aortic dissection intramural haematoma penetrating aortic ulcer
safety and efficacy study in in vitro fertilisation (ivf) patients

Conditions: Infertility

Summary: the purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous hmg preparations when administered to patients undergoing controlled ovarian stimulation for ivf.


Eligibility criteria:
inclusion criteria: * women undergoing ovarian stimulation for ivf with the following characteristics: * able and willing to sign the patient consent form and adhere to the study visitation schedule * \>18 and \<40 years old * bmi between 18 and 30 kg/m2 * less than 3 previously completed ivf cycles (i.e. completed cycle = egg recovery) * basal fsh \<10 iu/l and e2 \<80 pg/ml (\~290 pmol/l) * within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination * successful down-regulation performed with a standard gnrh-agonist long protocol (criteria for successful down-regulation: endometrial thickness \< 7mm or serum e2 level \<50 pg/ml (\~185 pmol/l). exclusion criteria: * age \ 40 years * primary ovarian failure or women known as poor responders (i.e. requiring more than 225 iu of hmg as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory e2 serum concentration \<500pg/ml (\~1800 pmol/l)) * pcos * one or both ovaries inaccessible for oocyte retrieval * ovarian cysts \>10 mm * hydrosalpinx that have not been surgically removed or ligated; * stage 3 or 4 endometriosis * oocyte donation * implantation of previously frozen embryos * patients affected by pathologies associated with any contraindication of being pregnant * hypersensitivity to the study medication * abnormal bleeding of undetermined origin * uncontrolled thyroid or adrenal dysfunction * neoplasias * severe impairment of renal and/or hepatic function * use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)
a canadian study of the effectiveness of tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with tresiba® (insulin degludec) for at least 6 months. data will be collected beginning 6 months before the participant started tresiba® up to around 6 months after the participant started taking insulin degludec.


Eligibility criteria:
inclusion criteria: * informed consent will be obtained before any study-related activities. study-related activities are any data collection from the medical records of the patient * male or female age greater than or equal to 18 years at the time of insulin degludec initiation * type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients * switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection * previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec * at least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation * minimum available data at the time of insulin degludec initiation: age, type of diabetes, hba1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (egfr) value in the last 12 ±6 months (full data period) exclusion criteria: * previous participation in this study. participation is defined as having signed the informed consent in this study * patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving tresiba
a study of anlotinib in recurrent/metastatic head and neck adenocarcinomas

Conditions: Head and Neck Carcinoma; Adenocarcinoma; Recurrent Disease; Distantly Metastatic Malignant Neoplasm

Summary: this is a non-randomized, phase ii, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. the primary purpose of this study is to evaluate the efficacy of anlotinib.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed head and neck adenocarcinoma. 2. patients with recurrent or metastatic head and neck adenocarcinoma who are not candidates for curative surgery or radiotherapy. 3. measurable disease per the recist criteria. 4. eastern cooperative oncology group (ecog) performance status 0-2. 5. provision of written informed consent. 6. childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (iud, birth control pills, or barrier device) during and for 3 months after completion of trial therapy. exclusion criteria: 1. prior treatment with anlotinib 2. with pleural effusion or ascites, cause respiratory syndrome 3. accepted the vascular endothelial growth inhibitor class targeted drug treatment of patients 4. plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including cytotoxic therapy, 5.signal transduction inhibitor, and immunotherapy (or who use mitomycin c within 6 weeks before taking the treatment with experimental drug); the patients who have already taken extended field radiotherapy (ef-rt) within 4 weeks before grouping or limited field radiotherapy with proposed assessment of nidus within 2 weeks before grouping 6.symptoms of brain metastases cannot be controlled and treated within less than 2 months 7.severe and failed to controlled diseases 8.occurred venous thromboembolic events within 6 months

Keywords: head and neck adenocarcinoma anlotinib
a study of dulaglutide (ly2189265) in children and adolescents with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. the study duration is approximately 60 weeks.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes, treated with diet and exercise, with or without metformin and/or basal insulin. metformin and/or basal insulin dose must be stable for at least 8 weeks prior to study screening. * have hba1c \>6.5% to ≤11% at screening visit. if newly diagnosed and not on medicine for diabetes, hba1c must be between \>6.5 % to ≤9%. * have a bmi (body mass index) \>85 percentile for age, gender and body weight ≥50 kilograms (110 pounds). exclusion criteria: * known type 1 diabetes, or positive gad65 or ia2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome. * a history of, or at risk for pancreatitis. * self or family history of multiple endocrine neoplasia (men) type 2a or b, thyroid c-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening. * a systolic blood pressure of ≥160 millimeters of mercury (mmhg) or diastolic ≥100 mmhg. * active or treated cancer. * a blood disorder where an accurate hba1c may not be obtainable. * a female of childbearing age, sexually active and not on birth control. * pregnant or plan to be pregnant during the study, or breastfeeding. * taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin). * have taken oral steroids within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day. * using prescription weight loss medications in the last 30 days, or plan to use. * taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (adhd) if, the doses has changed within the last 3 months.

Keywords: pediatrics
cortical bone plate versus cortico-cancellous block graft

Conditions: Horizontal Atrophy of Edentulous Alveolar Ridge

Summary: horizontal ridge augmentation using either cortical bone plate technique or cortico-cancellous block graft was the aim of the study. bone quality was analyzed histomorphomterically, and horizontal dimensional changes were assessed using cbct.


Eligibility criteria:
inclusion criteria: * eligible patients aged 18 years or older with partial edentulism of the mandible * the residual ridge width must be 4 mm or less * intra-oral donor sites should be available in the external oblique ridge and symphyseal area exclusion criteria: * patients with general contraindications for implant surgery such as uncontrolled diabetes * irradiation of the head and neck region * intravenous bisphosphonate * pregnancy * smokers, alcoholics and drug abusers

Keywords: split-bone block technique cortical bone plate cortico-cancellous block graft